Fig. 5: Comparison of the Benjamini-Hochberg significant pharmacogene expression changes between disease subgroups. | Nature Communications

Fig. 5: Comparison of the Benjamini-Hochberg significant pharmacogene expression changes between disease subgroups.

From: Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease

Fig. 5

A Upset plot showing the commonality in significantly changed pharmacogenes between disease subgroups. B Scatter plot showing mRNA percent change per unit of disease for the 17 pharmacogenes in common between all disease subgroups. For example, the plot shows that with each 1 unit increase in fibrosis stage, CYP2C19 transcript abundance decreases to 69% of the expression level at the prior stage. For each 1 unit increase in NAFLD activity score, CYP2C19 transcript abundance decreases to 83% of the expression level at the prior score. For each 1 unit increase in steatohepatitis grade, CYP2C19 transcript abundance decreases to 61% of the expression level at the prior grade. FIB fibrosis, NAS NAFLD activity score, STH steatohepatitis, BH Benjamini-Hochberg. Source data are provided in the supplemental materials.

Back to article page